Latest News for: inhibitor

Edit

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and ...

Longview News-Journal 21 Mar 2025
TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen ....
Edit

Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor

Nasdaq Globe Newswire 20 Mar 2025
CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company ...
Edit

PD-1 and PD-L1 Inhibitors Market: Trends, Growth, and Future Prospects

Pharmiweb 20 Mar 2025
PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune system to recognize and attack tumors ... How PD-1 and PD-L1 Inhibitors Work ... Inhibitors targeting PD-1 ...
Edit

U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease

PR Newswire 20 Mar 2025
"The approval of TREMFYA offers an IL-23 inhibitor that has shown robust rates of endoscopic remission with both subcutaneous and intravenous induction regimens.
Edit

Scientists discover new inhibitors of inflammation-related enzyme

Phys Dot Org 19 Mar 2025
... new inhibitors of the enzyme human 15-lipoxygenase-2 (h15-LOX-2).
Edit

EMPAVELI's Market Success Underscores Growing Demand for Complement Inhibitor Therapies | DelveInsight

PR Newswire 18 Mar 2025
LAS VEGAS, March 18, 2025 /PRNewswire/ -- DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a complement inhibitor indicated to treat adult patients with PNH ... C3 inhibitor.
Edit

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Nasdaq Globe Newswire 18 Mar 2025
New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors. New trial arm to evaluate safety, dosing and preliminary anti-tumor activity in advanced solid tumors ... .
Edit

Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®

PR Newswire 18 Mar 2025
-       MDSCs – Myeloid Derived Suppressor Cells in the tumor microenvironment are believed to reduce effectiveness of PD-1 inhibitors like KEYTRUDA® and OPDIVO®.
Edit

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory ...

Nasdaq Globe Newswire 17 Mar 2025
Antitumor activity observed with confirmed partial responses in 50% of patients. at highest dose tested to date, across multiple tumor types ... .
Edit

Treating chronic inflammatory diseases with JAK inhibitors

Science Daily 17 Mar 2025
Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic ...
Edit

VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor Competition | DelveInsight

PR Newswire 17 Mar 2025
VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type ... It functions as an inhibitor of TRK proteins (TRKA, TRKB, and TRKC) ... TRK inhibitor.
Edit

CeSPIACE: A broad spectrum peptide inhibitor against variable SARS-CoV-2 spikes

Phys Dot Org 14 Mar 2025
Blocking this interaction with inhibitors could prevent infection. Since these inhibitors ...
×